Search for a vaccine against AIDS gain momentum, with research published this week identified a promising new candidates that protected monkeys against strong pressure from the virus and that soon could be tested in humans.
Study published in the online edition of the journal Nature on Wednesday, also explained how the first human vaccine to have been given limited protection against the AIDS virus has worked.
In the study, some experimental vaccine prevented infection in monkey portion of tension which is very powerful, very resistant immunity simian immunodeficiency virus, looking for unusual, said researchers. SIV is similar to the human immunodeficiency virus or HIV, the virus that causes AIDS, and SIV infection in monkeys resembles that of HIV infection in humans.
New vaccines, combining two different technologies to produce an immune response, reduces the likelihood that the monkeys will be infected by a virulent strain of SIV in every exposure by 80 per cent to 83 per cent, compared with a placebo. The vaccine also significantly reduces the amount of virus in the blood monkeys who do become infected.
Protection is only part-most of the monkeys became infected after vaccination with multiple exposures. However, the study is among the first to prevent the infection of virulent, highly resistant strain of SIV immunity.